Palvella Therapeutics (PVLA) Other financing activities (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Other financing activities of $14.2 million for Q1 2026, up 21164.18% year-over-year from N/an in Q1 2025, and up 13468.57% quarter-over-quarter from $105000.0 in Q4 2025.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Other financing activities (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Other financing activities for 13 consecutive years, with $14.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 21164.18% year-over-year to $14.2 million; the TTM figure through Mar 2026 stood at $14.9 million (down 75.12% YoY), while the FY2025 annual figure was $763000.0, down 98.73% from the prior year.
- Other financing activities grew to $14.2 million in Q1 2026 per PVLA's latest filing, from $105000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $60.0 million in Q4 2024 and bottomed at -$52000.0 in Q4 2023.
- Historically, Other financing activities has averaged $6.3 million across 5 years, with a median of $93500.0 in 2022.
- Annual changes were most pronounced in 2023 — Other financing activities tumbled 150.98% — and 2024, when it surged 115486.54%.
- Palvella Therapeutics' Other financing activities stood at $102000.0 in 2022, then sank by 150.98% to -$52000.0 in 2023, then soared by 115486.54% to $60.0 million in 2024, then slumped by 99.83% to $105000.0 in 2025, then jumped by 13468.57% to $14.2 million in 2026.
- Business Quant data shows PVLA's Other financing activities at $14.2 million in Q1 2026, $105000.0 in Q4 2025, and $242000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 14.25 Mn |
| Dec 31, 2025 | 105,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Jun 30, 2025 | 349,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | 60.00 Mn |
| Dec 31, 2023 | -52,000.00 |
| Jun 30, 2023 | 52,000.00 |
| Dec 31, 2022 | 93,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 85,000.00 |
| Jun 30, 2021 | 9.24 Mn |
| Mar 31, 2021 | 9.67 Mn |
| Dec 31, 2020 | 20,000.00 |
| Jun 30, 2020 | 271,000.00 |
| Dec 31, 2019 | 335,000.00 |
| Sep 30, 2019 | 121,000.00 |
| Jun 30, 2019 | 97,000.00 |
| Dec 31, 2018 | 17,000.00 |
| Sep 30, 2018 | 100,000.00 |